ESMO 2014 - Immuno-Oncology

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent

Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent